Reglan Metoclopramide Tardive Dyskinesia Lawsuits
Contact us now for a Free Case Evaluation because we are presently filing our Reglan cases.
Metoclopramide is available under various trade names including Maxolon (Shire/Valeant), Reglan (Schwarz Pharma), Degan (Lek), Maxeran (Sanofi Aventis), Primperan (Sanofi Aventis), and Pylomid (Bosnalijek). If you have taken any Metoclopramide, we will evaluate your case.
Contact our Reglan/Metoclopramide lawyers at 314-678-1207 or Click here for Free Evaluation of your case.
FDA WARNING POINTS TO DANGERS OF LONG-TERM USE OF REGLAN; TWO MILLION AMERICANS WITH REFLUX DISEASE COULD BE AT RISK
The U.S. Food and Drug Administration has ordered the makers of the acid reflux medication Reglan to include a black box warning .The reason: the drug may lead to a serious condition known as tardive dyskinesia after chronic or high-dosage use.People with tardive dyskinesia experience involuntary, repetitive and purposeless movements.
Symptoms include:
Grimacing;
lip smacking;
puckering or pursing of the lips;
rapid eye blinking,
rapid movement of extremities;
and impaired movement of the fingers.
If you or a loved one have taken Reglan (Generic name: Metoclopramide) and been diagnosed with Tardive Dyskinesia (“TD”), you should contact us immediately. You may be entitled to compensation and we can help.Metoclopramide (INN) is an antiemetic and gastroprokinetic agent. Thus it is primarily used to treat nausea and vomiting, and to facilitate gastric emptying in patients with gastroparesis.
The manufacturers of Reglan and its generic metoclopramide mention the link between the development of TD and the drug on its labeling, nevertheless, they suggest the incidence rarely occurs.It is important to understand that the Food & Drug Administration has only approved Reglan for short-term use (4 to 12 weeks) and only when conservative treatment fails.
Safety experts from the Duke University School of Medicine, publishing in the November/December 2004 Journal of the American Pharmacists Association, caution that the use of Reglan is increasing and that this fact may result in more cases of drug-induced movement disorders from the medication.
Contact us now for a Free Case Evaluation because we are presently filing our Reglan cases.
Metoclopramide is available under various trade names including Maxolon (Shire/Valeant), Reglan (Schwarz Pharma), Degan (Lek), Maxeran (Sanofi Aventis), Primperan (Sanofi Aventis), and Pylomid (Bosnalijek). If you have taken any Metoclopramide, we will evaluate your case.
Contact our Reglan/Metoclopramide lawyers at 314-678-1207 or Click here for Free Evaluation of your case.
FDA WARNING POINTS TO DANGERS OF LONG-TERM USE OF REGLAN; TWO MILLION AMERICANS WITH REFLUX DISEASE COULD BE AT RISK
The U.S. Food and Drug Administration has ordered the makers of the acid reflux medication Reglan to include a black box warning .The reason: the drug may lead to a serious condition known as tardive dyskinesia after chronic or high-dosage use.People with tardive dyskinesia experience involuntary, repetitive and purposeless movements.
Symptoms include:
Grimacing;
lip smacking;
puckering or pursing of the lips;
rapid eye blinking,
rapid movement of extremities;
and impaired movement of the fingers.
If you or a loved one have taken Reglan (Generic name: Metoclopramide) and been diagnosed with Tardive Dyskinesia (“TD”), you should contact us immediately. You may be entitled to compensation and we can help.Metoclopramide (INN) is an antiemetic and gastroprokinetic agent. Thus it is primarily used to treat nausea and vomiting, and to facilitate gastric emptying in patients with gastroparesis.
The manufacturers of Reglan and its generic metoclopramide mention the link between the development of TD and the drug on its labeling, nevertheless, they suggest the incidence rarely occurs.It is important to understand that the Food & Drug Administration has only approved Reglan for short-term use (4 to 12 weeks) and only when conservative treatment fails.
Safety experts from the Duke University School of Medicine, publishing in the November/December 2004 Journal of the American Pharmacists Association, caution that the use of Reglan is increasing and that this fact may result in more cases of drug-induced movement disorders from the medication.
